We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EYE:NASDAQNational Vision Holdings, Inc. Analysis

Data as of 2026-06-30 - not real-time

$18.79

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

National Vision Holdings (EYE) is trading below its fair value and well under the 52‑week high, suggesting a material upside potential. The stock’s price sits between the 20‑day and 50‑day moving averages, with the 20‑day SMA below current levels, indicating a short‑term floor but a longer‑term bearish bias as it remains under the 200‑day SMA. Momentum indicators are mixed: the RSI hovers in the neutral zone while the MACD histogram turned positive, giving a modest bullish signal. Volume has been on the rise, supporting the recent price stability and hinting at renewed buying interest. Insider activity adds confidence, as director Michael Nicholson purchased a sizable block of shares shortly after earnings, signaling internal belief in the company’s prospects. Earnings released a month ago showed modest revenue growth of roughly 6‑7% and solid gross margins, though operating and net margins remain thin.
The balance sheet is leveraged, with debt levels markedly higher than cash, which could constrain flexibility in a downturn. Nonetheless, free cash flow remains positive, providing a cushion for ongoing operations and potential debt reduction. The consumer‑cyclical nature of the optical retail sector makes the stock sensitive to discretionary spending, yet demographic trends of aging populations support long‑term demand. The market sentiment index is in “Extreme Greed,” reflecting overall bullishness that may lift the stock in the near term. Valuation metrics, including a forward PE under 16 and a price‑to‑book below 2, place the company in the “fair‑to‑undervalued” range relative to peers. Considering these factors, the stock appears positioned for a potential rebound, but investors should remain mindful of volatility and leverage risks.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Neutral technical positioning with price near support
  • Insider buying indicating confidence
  • Positive MACD momentum

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Valuation upside relative to DCF
  • Improving earnings guidance
  • Positive free cash flow

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Demographic tailwinds for vision care
  • Stable brand footprint across the U.S.
  • Long‑term undervaluation per DCF analysis

Key Metrics & Analysis

Financial Health

Revenue Growth6.60%
Profit Margin2.31%
P/E Ratio33.0
ROE5.37%
ROA2.63%
Debt/Equity77.07
P/B Ratio1.7
Op. Cash Flow$175.8M
Free Cash Flow$124.8M

Technical Analysis

TrendBearish
RSI55.8
Support$14.93
Resistance$19.18
MA 20$17.14
MA 50$19.41
MA 200$24.96
MACDBullish
VolumeIncreasing
Fear & Greed Index90.09

Valuation

Fair Value$19.83
Target Price$29.27
Upside/Downside55.83%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.23
Volatility55.13%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.